Royalty Pharma plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| RPRX | ROIV | REGN | 3759.HK | 0NZU.IL | LGND | |
|---|---|---|---|---|---|---|
| Market cap | 39.04B | 27.61B | 96.28B | 55.85B | 14.45B | 6.32B |
| P/E (TTM) | 44.2 | — | 20.6 | 27.4 | — | 127.0 |
| Forward P/E | 11.6 | -27.5 | 13.2 | 17.2 | — | 25.9 |
| Price/book | 4.5 | 6.5 | 2.8 | 2.8 | 8.2 | 6.6 |
| Dividend yield | 1.39% | — | 0.40% | 0.78% | — | — |
| 1-year change | +64.28% | +78.15% | +51.10% | +19.72% | −50.69% | +64.68% |
| Today | +1.75% | +6.08% | −4.39% | +3.47% | +1.66% | +0.83% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All RPRX news ›Should You Buy Royalty Pharma Stock Before Nov. 4?
Royalty Pharma (RPRX -0.70%) will report Q3 2026 earnings pre-market on Nov. 4. After pulling back in September due to a major setback with one of its drug candidates, the pharmaceutical royalty holding company's shares have been soaring…
Pharma Mar (PHMMF) Projected to Release Earnings on Thursday
Posted by Defense World Staff on Oct 28th, 2026 Pharma Mar (OTCMKTS:PHMMF – Get Free Report) will likely be posting its resultson Thursday, October 29th. Analysts expect Pharma Mar to post earnings of $0.0038 per share and revenue of…
Analyzing Nexentis Technologies (NASDAQ:NXTS) & Royalty Pharma (NASDAQ:RPRX)
Posted by Danessa Lincoln on Oct 27th, 2026 Nexentis Technologies (NASDAQ:NXTS – Get Free Report) and Royalty Pharma (NASDAQ:RPRX – Get Free Report) are both healthcare companies, but which is the better business? We will contrast the two…
Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead
Royalty Pharma invests in a portfolio of drugs, from blockbusters to those still in development. Biotech companies are high-risk, high-reward investments. Usually, a biotech has just one drug in development, and if it gets that drug to…
Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder
Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs. Read why PTGX stock is a Buy. - Protagonist Therapeutics has evolved into a royalty-driven company with two FDA-approved drugs, robust…
Head to Head Review: Royalty Pharma (NASDAQ:RPRX) versus Biofrontera (NASDAQ:BFRI)
Posted by Tristan Rich on Oct 25th, 2026 Biofrontera (NASDAQ:BFRI – Get Free Report) and Royalty Pharma (NASDAQ:RPRX – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses…
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
NEW YORK, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026 before the U.S ... 09, 2026 (GLOBE NEWSWIRE) --…
Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million
Ligand Pharmaceuticals said Tuesday it has acquired a tiered royalty interest in Santen Pharmaceutical's Ryjunea from Sydnexis for an upfront payment of $23 million. Under the deal, Ligand said it... Ligand Pharmaceuticals Acquires Ryjunea…
3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell
Pharmaceutical companies search for and develop drugs that they hope will one day generate large profits. However, the drug discovery process is complex, competitive, and costly. This is where Royalty Pharma comes in. Royalty Pharma…
Analyzing Royalty Pharma (NASDAQ:RPRX) and Chugai Pharmaceutical (OTCMKTS:CHGCY)
Posted by Tristan Rich on Oct 23rd, 2026 Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) and Royalty Pharma (NASDAQ:RPRX – Get Free Report) are both large-cap healthcare companies, but which is the superior stock? We will compare…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com10
- fool.com4
- themarketsdaily.com4
- marketbeat.com3
- pluang.com3
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 36 articles, not a forecast.